Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis
View/ Open
Author
Nairz, Manfred
Haschka, David
Dichtl, Stefanie
Sonnweber, Thomas
Schroll, Andrea
Aßhoff, Malte
Moser, Patrizia L.
Wolf, Dominik
Theurl, Igor
Cerami, Anthony
Brines, Michael
Weiss, Günter
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/s41598-017-13046-3Metadata
Show full item recordCitation
Nairz, M., D. Haschka, S. Dichtl, T. Sonnweber, A. Schroll, M. Aßhoff, J. E. Mindur, et al. 2017. “Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.” Scientific Reports 7 (1): 13012. doi:10.1038/s41598-017-13046-3. http://dx.doi.org/10.1038/s41598-017-13046-3.Abstract
Two distinct forms of the erythropoietin receptor (EPOR) mediate the cellular responses to erythropoietin (EPO) in different tissues. EPOR homodimers signal to promote the maturation of erythroid progenitor cells. In other cell types, including immune cells, EPOR and the ß-common receptor (CD131) form heteromers (the innate repair receptor; IRR), and exert tissue protective effects. We used dextran sulphate sodium (DSS) to induce colitis in C57BL/6 N mice. Once colitis was established, mice were treated with solvent, EPO or the selective IRR agonist cibinetide. We found that both cibinetide and EPO ameliorated the clinical course of experimental colitis in mice, resulting in improved weight gain and survival. Correspondingly, DSS-exposed mice treated with cibinetide or EPO displayed preserved tissue integrity due to reduced infiltration of myeloid cells and diminished production of pro-inflammatory disease mediators including cytokines, chemokines and nitric oxide synthase-2. Experiments using LPS-activated primary macrophages revealed that the anti-inflammatory effects of cibinetide were dependent on CD131 and JAK2 functionality and were mediated via inhibition of NF-κB subunit p65 activity. Cibinetide activation of the IRR exerts potent anti-inflammatory effects, especially within the myeloid population, reduces disease activity and mortality in mice. Cibinetide thus holds promise as novel disease-modifying therapeutic of inflammatory bowel disease.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638901/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492453
Collections
- FAS Scholarly Articles [18292]
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)